首页> 外文期刊>World Journal of Surgical Oncology >Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells
【24h】

Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells

机译:吉非替尼载有CD133适体的DSPE-PEG2000纳米胶束靶向肺癌干细胞

获取原文
获取外文期刊封面目录资料

摘要

Background Lung cancer stem cells (CSCs) are considered to be the seed of lung cancer, and CD133 is a marker of lung CSCs. Here, we developed gefitinib-loaded poly(ethylene glycol) 2000-distearoylphosphatidylethanolamine nanomicelles with CD133 aptamers (M-Gef-CD133) to eliminate CD133+ lung CSCs. Methods M-Gef-CD133 was prepared using a lipid-film-based approach. The targeting and activity of M-Gef-CD133 towards lung CSCs were evaluated. Results M-Gef-CD133 were small (25?nm) and showed enhanced cytotoxic effect towards CD133+ lung CSCs compared with non-targeted M-Gef and gefitinib. Notably, M-Gef-CD133 could significantly reduce tumor sphere formation and the percentage of CD133+ lung CSCs, indicating that it possesses selective toxicity against CD133+ lung CSCs. Conclusions The interaction of CD133 aptamers and CD133 shows promise in the delivery of gefitinib to CD133+ lung CSCs, and M-Gef-CD133 represents a promising treatment to target lung CSCs.
机译:背景技术肺癌干细胞(CSC)被认为是肺癌的种子,而CD133是肺CSC的标志物。在这里,我们开发了含有吉非替尼的聚乙二醇2000-二硬脂酰磷脂酰乙醇胺纳米胶束和CD133适体(M-Gef-CD133),以消除CD133 + 肺CSC。方法采用脂膜法制备M-Gef-CD133。评价了M-Gef-CD133对肺CSC的靶向性和活性。结果M-Gef-CD133较小(25?nm),与非靶向M-Gef和吉非替尼相比,对CD133 + 肺CSCs具有增强的细胞毒性作用。值得注意的是,M-Gef-CD133可以显着减少肿瘤球的形成和CD133 + 肺CSC的百分比,表明它对CD133 + 肺CSC具有选择性毒性。结论CD133适体与CD133的相互作用在吉非替尼向CD133 + 肺CSC的递送中显示出希望,而M-Gef-CD133是靶向肺CSC的有前途的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号